Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Long-Term Genome-Wide Blood RNA Expression Profiles Yield Novel Molecular Response Candidates for IFN-β-1b Treatment in Relapsing Remitting MS

1 Feb 2010

Abstract excerpt

AIMS: In multiple sclerosis patients, treatment with recombinant IFN-beta (rIFN-beta) is partially efficient in reducing clinical exacerbations. However, its molecular mechanism of action is still under scrutiny. MATERIALS & METHODS: We used DNA microarrays (Affymetrix, CA, USA) and peripheral mononuclear blood cells from 25 relapsing remitting multiple sclerosis patients to analyze the longitudinal...

Topics

Join the communities discussing this publication.

Bioinformatics and Genomic Networks
Gene expression and cancer classification
Multiple Sclerosis Research Studies

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 20136355
DOI: 10.2217/pgs.09.152

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-Term Genome-Wide Blood RNA Expression Profiles Yield Novel Molecular Response Candidates for IFN-β-1b Treatment in Relapsing Remitting MSPMID 20136355Read ↗

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between PatientsSemantic proximity Read ↗

Time course transcriptomics of IFNB1b drug therapy in multiple sclerosisSemantic proximity Read ↗

Genomic effects of IFN-beta in multiple sclerosis patients.Semantic proximity Read ↗

Gene expression analysis of interferon-β treatment in multiple sclerosisSemantic proximity Read ↗

Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosisSemantic proximity Read ↗

Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genesSemantic proximity Read ↗

IFN-β-regulated genes show abnormal expression in therapy-naïve relapsing–remitting MS mononuclear cells: Gene expression analysis employing all reported protein–protein interactionsSemantic proximity Read ↗

GEO Data Sets Analysis On Mechanism of Action of IFNβ-1a Treatment in Multiple SclerosisSemantic proximity Read ↗

Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-betaSemantic proximity Read ↗

Gene Expression Profiling of the Response to Interferon Beta in Epstein-Barr-Transformed and Primary B Cells of Patients with Multiple SclerosisSemantic proximity Read ↗

An RNA Profile Identifies Two Subsets of Multiple Sclerosis Patients Differing in Disease ActivitySemantic proximity Read ↗

Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.